For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Sun Pharma gets USFDA approval for acne drug

By Religare
|

Sun Pharmaceutical Industries said it has received approval from the US health regulator for its new drug application for acne treatment medicine--XiminoTM extended-release capsules, reported PTI.

The US Food and Drug Administration (USFDA) has approved the company's supplemental New Drug Application (sNDA) for XiminoTM (Minocycline HCl) extended-release capsules in strengths of 45 mg, 90 mg and 135 mg, Sun Pharma said in a statement.

XiminoTM extended-release capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

 

"This approval further strengthens the company's branded dermatology portfolio in the US. It expects XiminoTM extended-release capsules to be available for patients during the fourth quarter of 2015," the Mumbai-based company said.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical firm.

The company's consolidated revenues for 12 months ended March 2015 stood at around USD 4.5 billion, of which US contributed USD 2.2 billion.

Story first published: Thursday, August 20, 2015, 9:10 [IST]
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Find IFSC

We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more